VAL is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company has two leading assets: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potential to treat other hormone-induced indications; and VAL401 (completed Phase II) – a novel reformulation of risperidone, for advanced lung cancer. Both drugs are targeted at multi-billion-dollar markets that are inadequately served by current drugs. VAL is in a joint venture with the SEEK group for the VAL401 programme, with ValiSeek having agreed Letters of Intent with two partners to progress VAL401 further into the clinic.
15 Apr 2019
VAL401 is going forward
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
VAL401 is going forward
ValiRx PLC (VAL:LON) | 3.4 0 0.0% | Mkt Cap: 4.57m
- Published:
15 Apr 2019 -
Author:
Martin Hall -
Pages:
4
VAL is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company has two leading assets: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potential to treat other hormone-induced indications; and VAL401 (completed Phase II) – a novel reformulation of risperidone, for advanced lung cancer. Both drugs are targeted at multi-billion-dollar markets that are inadequately served by current drugs. VAL is in a joint venture with the SEEK group for the VAL401 programme, with ValiSeek having agreed Letters of Intent with two partners to progress VAL401 further into the clinic.